LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-05 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
In the mid-1990s the NHS in the UK took the bold step of making this a universal feature of result delivery to general practice (GPs) and embarked on two linked projects to achieve this. In the first, the Pathology Messaging Enabler Project, standards were defined and infrastructure installed to link 200 laboratory systems to 8,500 GP systems. In the second project, the Pathology Messaging Implementation Project, these standards and the associated software was rolled out. By 2004 more than 35 million results messages were being transmitted each year and in 2007 some 50 million such messages were safely and securely delivered. During the 12 months to July 2023, 1.88 Billion discrete new EPR items added to electronic patient records held by UK GPs were expressed using a code from within the PBCL, accompanied (usually) by a value and a unit of measurement. The PMIP EDIFACT+PBCL system remains the prevailing technology supporting all GP laboratory requesting and resulting across the entire UK, but the strategic national intent since the early 2020s has been to migrate all live GP systems to FHIR and the Unified Test List, a new and bespoke national extension of SNOMED CT offering greater detail. Although it is hoped this migration will remove the discordant standards used between UK primary and secondary care, as of August 2024 the migration has yet to begin.
In May 2006, Valve announced a trilogy of episodic games that would continue the Half-Life 2 story, with the final episode planned for release by Christmas 2007. Valve's president, Gabe Newell, said the approach would allow Valve to release products more quickly after the six-year Half-Life 2 development, and that he considered the trilogy the equivalent of Half-Life 3. According to Newell, where Half-Life saw the G-Man transform Freeman into his tool, and Half-Life 2 saw Freeman being used by G-Man, the episodes would see G-Man lose control. Episode One was released on June 1, 2006. The player controls Freeman as he and Alyx escape City 17 before a dark energy reactor core destroys it. It introduced several graphical effects, including new lighting features and more advanced facial animation. The story focuses on Alyx. Episode One received a generally positive critical reaction, although the short length was a common point of criticism.
== Interactions == Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves. It may also potentiate the CNS depressant effects of alcohol. It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbital) and itself. It may also interact with:
=== Infrastructure === As Minister, McNaughton introduced Bill 32, the Access to Natural Gas Act, in the fall of 2018. It was passed into law that December. Bill 32 was intended to make it possible to expand access to natural gas throughout rural and Northern Ontario, including First Nations communities. Premier Ford said in a statement released on September 17, 2018, that "cancelling the cap-and-trade carbon tax" had caused the price of natural gas to decrease in Ontario. Premier Ford announced the new legislation and explained how it differed from the previous government's 2017 taxpayer-funded $100 million Natural Gas Grant Program—through which—according to Premier Ford, "private sector companies were limited from participating in natural gas expansion, portions of which were instead managed by the [Natural Gas Grant Program]." Bill 32, the Access to Natural Gas Act passed into law in 2018 to "encourage more private gas distributors to partner with communities to develop projects that expand access to affordable and efficient natural gas." On September 18, 2018, the city of North Bay learned that the Natural Gas Grant Program funding of over $8.6 million had been cancelled for a natural gas project that would have extended "services to as many as 350 homes in the north shore area of Trout Lake." In January 2019, Minister McNaughton announced that the Ford government would provide $27 million to Northeast Midstream towards the construction of their Nipigon LNG gas plant.
Sources: en.wikipedia.org
Buprenorphine/naltrexone is an experimental combination drug formulation of buprenorphine, a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor (KOR) antagonist, and naltrexone, a MOR and KOR silent antagonist, which is under investigation for the potential treatment of psychiatric disorders. The combination of the two drugs is thought to result in a selective blockade of the KOR and hence fewer MOR activation-related concerns such as euphoria and opioid dependence. It has been found to produce antidepressant-like effects in mice (similarly to the case of buprenorphine alone or in combination with samidorphan) and (at a buprenorphine dosage of 16 mg/day but not 4 mg/day) has recently been found to be effective in the treatment of cocaine dependence in a large clinical trial.
==== Concerns ==== An analysis conducted in late 2020 of premarket vaccine purchase commitments indicated that wealthy countries may receive their vaccines in 2020–21 while developing countries may be excluded from vaccinations until 2023–24. Data from April 2021 comports with this expectation since 25% of the population in high income countries have been vaccinated compared to only 0.2% in low income countries. The head of the World Health Organization said on 4 August 2021 that rich countries had administered about 100 doses per 100 people while poor countries had administered only about 1.5 doses for every 100 people, and therefore, in his estimation, it was important to prioritize vaccination in poor countries before offering booster vaccines in rich countries. The WHO Director General Tedros Adhanom Ghedreyesus raised concerns about rich countries hoarding vaccines at the expense of citizens in poorer nations who wait for vaccines to either become available or are donated. The WHO Regional Office of Africa highlighted vaccine discard in African countries, after Nigeria destroyed about 1 million donated doses of AstraZeneca vaccine after being donated with only a few weeks till expiration. Other countries such as Malawi, and South Sudan have either destroyed expired or close to expiring vaccines or paused donated shipments due to expiration concerns.
Sideways gives an accurate depiction of depression. Depression (major depressive disorder) is characterized as a mood disorder that causes severe feelings of sadness and disinterest. One of the movie's main characters, Miles Raymond, is shown to exhibit several signs of depression, some of which include using substances (alcohol) in an attempt to cope with the failures and losses in his life, not having hope for his future, and having a consistently depressed mood. Julien Donkey Boy gives an accurate depiction of schizophrenia. Schizophrenia is one of the most commonly misunderstood mental illnesses, yet over 2 million people suffer from this illness within the U.S. The term schizophrenia comes from Eugen Bleuler and translates to "split psyche," as the psyche is split into many disorganized parts. Symptoms include, but are not limited to, delusions, hallucinations, and disturbances in thoughts and emotions. These symptoms prohibit those suffering from this illness from leading a normal life, causing social and occupational dysfunction, often necessitating hospitalization. The movie features a man named Julien, who exhibits several signs of schizophrenia. One of these signs includes having conversations with people who are not there in reality. Silver Linings Playbook gives an accurate depiction of bipolar disorder. Bipolar disorder is a mental illness characterized by a dysregulation of mood, often accompanied by depressive and manic episodes, anxiety, hyperactivity, irregular sleep, aggressiveness, and irritability.
Sources: en.wikipedia.org
=== Hybrid documentary === The release of The Thin Blue Line (1988) directed by Errol Morris introduced possibilities for emerging forms of the hybrid documentary. Indeed, it was disqualified for an Academy Award because of the stylized recreations. Traditional documentary filmmaking typically removes signs of fictionalization to distinguish itself from fictional film genres. Audiences have recently become more distrustful of the media's traditional fact production, making them more receptive to experimental ways of telling facts. The hybrid documentary implements truth games to challenge traditional fact production. Although it is fact-based, the hybrid documentary is not explicit about what should be understood, creating an open dialogue between subject and audience. Clio Barnard's The Arbor (2010), Joshua Oppenheimer's The Act of Killing (2012), Mads Brügger's The Ambassador, and Alma Har'el's Bombay Beach (2011) are a few notable examples.
== Uses == In the 1970s and 1980s, the proportionately largest use of these polymers was in water treatment. The next major application by weight is additives for pulp processing and papermaking. About 30% of polyacrylamide is used in the oil and mineral industries.
=== Admission to hospital === Patients with AN may be deemed to have a lack of insight regarding the necessity of treatment, and thus may be involuntarily treated without their consent. AN has a high mortality and patients admitted in a severely ill state to medical units are at particularly high risk. Diagnosis can be challenging, risk assessment may not be performed accurately, consent and the need for compulsion may not be assessed appropriately, refeeding syndrome may be missed or poorly treated and the behavioural and family problems in AN may be missed or poorly managed. Guidelines published by the Royal College of Psychiatrists recommend that medical and psychiatric experts work together in managing severely ill people with AN.
Caution should be exercised when collecting specimens from potentially polluted or contaminated sites, as several studies have shown that the fruit bodies can bioaccumulate toxic heavy metals like mercury, cadmium, caesium and polonium. Bioaccumulated metals or radioactive fission decay products are like chemical signatures: chemical and radiochemical analysis can be used to identify the origin of imported specimens, and for long-term radioecological monitoring of polluted areas. Porcini are sold fresh in markets in summer and autumn in Europe and Russia, and dried or canned at other times of the year, and distributed worldwide to countries where they are not otherwise found. They are eaten and enjoyed raw, sautéed with butter, ground into pasta, in soups, and in many other dishes. In France, they are used in recipes such as cèpes à la Bordelaise, cèpe frits and cèpe aux tomates. Porcini risotto is a traditional Italian autumn dish. Porcini are a feature of many cuisines, including Provençal, and Viennese. In Thailand they are used in soups and consumed blanched in salads. Porcini can also be frozen, either while raw or after cooking in butter. The colour, aroma, and taste of porcini deteriorate noticeably after being frozen for four months. Blanching (or soaking and blanching) as a processing step before freezing can extend the freezer life to 12 months. They are also one of the few species sold commercially as pickled mushrooms.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.